Cargando…

Advanced Bladder Cancer: Changing the Treatment Landscape

Bladder cancer is the 10th most common cancer type in the world. There were more than 573,000 new cases of bladder cancer in 2020. It is the 13th most common cause of cancer death with an estimated more than 212,000 deaths worldwide. Low-grade non-muscle-invasive bladder cancer (NMIBC) is usually su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilim, Vladimir, Kuroki, Hiroo, Shirono, Yuko, Murata, Masaki, Hiruma, Kaede, Tomita, Yoshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604712/ https://www.ncbi.nlm.nih.gov/pubmed/36294884 http://dx.doi.org/10.3390/jpm12101745

Ejemplares similares

Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells
por: Shirono, Yuko, et al.
Publicado: (2023)

Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma
por: Kazama, Akira, et al.
Publicado: (2022)

MicroRNAs as Potential Regulators of GSK-3β in Renal Cell Carcinoma
por: Murata, Masaki, et al.
Publicado: (2023)

Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment
por: Kuroki, Hiroo, et al.
Publicado: (2021)

Development of patient-derived tumor organoids and a drug testing model for renal cell carcinoma
por: Kazama, Akira, et al.
Publicado: (2021)

Ulcerative interstitial cystitis in an adolescent successfully treated with complete transurethral ulcer resection: A case report
por: Yuki, Eri, et al.
Publicado: (2018)

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
por: Kuroki, Hiroo, et al.
Publicado: (2019)

Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
por: Anraku, Tsutomu, et al.
Publicado: (2020)

Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non‐muscle‐invasive bladder cancer (NMIBC)
por: Bilim, Vladimir, et al.
Publicado: (2022)

Changing landscape of diagnosis and treatment of bladder cancer
por: Kim, Wun-Jae
Publicado: (2016)

A Case of Myxoid Adrenocortical Neoplasm: Computed Tomography and Magnetic Resonance Imaging Characteristics
por: Fukuhara, Hiroki, et al.
Publicado: (2013)

Congenital Scaphoid Megalourethra: A Case Report
por: Obara, Kenji, et al.
Publicado: (2017)

Megalourethra and bladder foreign body in a female patient
por: Bilim, Vladimir, et al.
Publicado: (2023)

Virilization of a female infant genitalia caused by a maternal androgen-producing adrenocortical tumor: A case report
por: Hoshino, Sayaka, et al.
Publicado: (2020)

Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2023)

Intraoperative intraocular pressure changes during robot-assisted radical prostatectomy: associations with perioperative and clinicopathological factors
por: Shirono, Yuko, et al.
Publicado: (2020)

New discoveries in the molecular landscape of bladder cancer
por: Li, Roger, et al.
Publicado: (2016)

Mutational Landscape and Environmental Effects in Bladder Cancer
por: Hayashi, Takuji, et al.
Publicado: (2020)

GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition
por: Ito, Hiromi, et al.
Publicado: (2016)

Recent advances in the diagnosis and treatment of bladder cancer
por: Cheung, Grace, et al.
Publicado: (2013)

Evolving treatment landscape for early and advanced pancreatic cancer
por: Lau, Sally C, et al.
Publicado: (2017)

The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas
por: Hahn, Andrew W., et al.
Publicado: (2020)

Multiple endocrine disorders manifested as gynecomastia in a patient with renal pelvis cancer
por: Bilim, Vladimir, et al.
Publicado: (2022)

Enzalutamide‐induced severe thrombocytopenia complicated by a seizure in a 76‐year‐old man with castration‐resistant prostate cancer
por: Murata, Masaki, et al.
Publicado: (2018)

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer
por: Kong, Chenfan, et al.
Publicado: (2022)

Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects
por: Hu, Henglong, et al.
Publicado: (2022)

Editorial Comment from Dr Bilim to Testicular sarcoidosis with bilateral scrotal swelling
por: Bilim, Vladimir
Publicado: (2019)

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers
por: Matuszczak, Milena, et al.
Publicado: (2022)

Metastatic Urothelial Cancer: a rapidly changing treatment landscape
por: Stecca, Carlos, et al.
Publicado: (2021)

The landscape of genetics and biomarkers in bladder cancer
por: Rink, Michael
Publicado: (2017)

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
por: Iwamoto, Hideki, et al.
Publicado: (2023)

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
por: Aydin, Ahmet Murat, et al.
Publicado: (2017)

BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets
por: Claps, Francesco, et al.
Publicado: (2023)

Advances in Diagnosis and Therapy for Bladder Cancer
por: Hu, Xinzi, et al.
Publicado: (2022)

The evolving immunotherapeutic landscape in advanced oesophagogastric cancer
por: Flynn, Michael, et al.
Publicado: (2018)

The changing treatment landscape in idiopathic pulmonary fibrosis
por: Costabel, Ulrich
Publicado: (2015)

Active surveillance for nonmuscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2016)

Bladder cancer metastasis producing beta‐human chorionic gonadotropin, squamous cell carcinoma antigen, granulocyte‐colony stimulating factor, and parathyroid hormone‐related protein
por: Hoshi, Senji, et al.
Publicado: (2018)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

The Changing Landscape of Alopecia Areata: The Translational Landscape
por: Wang, Etienne C. E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_is6i527vlrphunla65ki0dsh6h